Cargando…

Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer

A retrospective study was conducted to investigate the efficacy and toxicity of single-agent nab-paclitaxel in 67 patients with platinum-resistant non-small cell lung cancer in Kansai Medical University Hospital from August 2013 to December 2015. Overall, 25% of patients experienced disease progress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakaya, Aya, Kurata, Takayasu, Yokoi, Takashi, Takeyasu, Yuki, Niki, Maiko, Kibata, Kayoko, Satsutani, Naoko, Torii, Yoshitaro, Katashiba, Yuichi, Ogata, Makoto, Miyara, Takayuki, Nomura, Shosaku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700274/ https://www.ncbi.nlm.nih.gov/pubmed/29181169 http://dx.doi.org/10.3892/mco.2017.1392

Ejemplares similares

Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation
por: Kurata, Takayasu, et al.
Publicado: (2017)

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer
por: Nakatani, Yuki, et al.
Publicado: (2017)

Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
por: Nakaya, Aya, et al.
Publicado: (2018)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Retrospective analysis of bevacizumab‐induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer
por: Nakaya, Aya, et al.
Publicado: (2016)

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
por: Niki, Maiko, et al.
Publicado: (2018)

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
por: Niki, Maiko, et al.
Publicado: (2017)

Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer
por: SHIMIZU, TOSHIKI, et al.
Publicado: (2013)

Antiplatelet antibody may cause delayed transfusion-related acute lung injury
por: Torii, Yoshitaro, et al.
Publicado: (2011)

The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells
por: Kibata, Kayoko, et al.
Publicado: (2019)

Statins can suppress DC‐mediated Th2 responses through the repression of OX40‐ligand and CCL17 expression
por: Inagaki‐Katashiba, Noriko, et al.
Publicado: (2019)

Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
por: KIBATA, KAYOKO, et al.
Publicado: (2013)

Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer
por: Yu, Xiao-Li, et al.
Publicado: (2021)

Primary intrahepatic malignant mesothelioma with multiple lymphadenopathies due to non-tuberculous mycobacteria: A case report and review of the literature
por: INAGAKI, NORIKO, et al.
Publicado: (2013)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017)

Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study
por: Wang, Liangliang, et al.
Publicado: (2023)

nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Kokubu, Hiraku, et al.
Publicado: (2023)

Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis
por: Tan, Tianying, et al.
Publicado: (2023)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

Primary dural high grade B cell lymphoma mimicking subdural hematoma
por: Nakaya, Aya, et al.
Publicado: (2021)

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Patel, Shetal A., et al.
Publicado: (2021)

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020)

Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report
por: Ogata, Makoto, et al.
Publicado: (2011)

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
por: Al-Hajeili, Marwan, et al.
Publicado: (2014)

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
por: Alvarez, R, et al.
Publicado: (2013)

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion
por: Singh, Harjinder, et al.
Publicado: (2023)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020)

Six cases of autoimmune acquired coagulation factor VIII deficiency: Single center experience in Japan
por: Konishi, Akiko, et al.
Publicado: (2020)

Phase I/II study of biweekly nab‐paclitaxel in patients with platinum‐pretreated non‐small cell lung cancer: NJLCG1402
por: Miyauchi, Eisaku, et al.
Publicado: (2021)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
por: Katsurada, Naoko, et al.
Publicado: (2020)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study
por: Sugiyama, Keiji, et al.
Publicado: (2019)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
por: Yamamoto, Yutaka, et al.
Publicado: (2011)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
por: Vishnu, Prakash, et al.
Publicado: (2011)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
por: De Luca, Rossella, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_90h5dm0oddmi6oi485k9po7i44